BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Di Costanzo GG, Tortora R. Intermediate hepatocellular carcinoma: How to choose the best treatment modality? World J Hepatol 2015; 7(9): 1184-1191 [PMID: 26019734 DOI: 10.4254/wjh.v7.i9.1184] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Sayan M, Yegya-Raman N, Greco SH, Gui B, Zhang A, Chundury A, Grandhi MS, Hochster HS, Kennedy TJ, Langan RC, Malhotra U, Rustgi VK, Shah MM, Spencer KR, Carpizo DR, Nosher JL, Jabbour SK. Rethinking the Role of Radiation Therapy in the Treatment of Unresectable Hepatocellular Carcinoma: A Data Driven Treatment Algorithm for Optimizing Outcomes. Front Oncol 2019;9:345. [PMID: 31275846 DOI: 10.3389/fonc.2019.00345] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
2 Chen XZ, Zhang WK, Tang HB, Li XJ, Tian GH, Shang HC, Li YS. The Ethanol Supernatant Extracts of Liushenwan Could Alleviate Nanodiethylnitrosamine-Induced Liver Cancer in Mice. Can J Gastroenterol Hepatol 2018;2018:6934809. [PMID: 30356380 DOI: 10.1155/2018/6934809] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
3 Bhutiani N, Philips P, Scoggins CR, McMasters KM, Potts MH, Martin RC. Evaluation of tolerability and efficacy of irreversible electroporation (IRE) in treatment of Child-Pugh B (7/8) hepatocellular carcinoma (HCC). HPB (Oxford). 2016;18:593-599. [PMID: 27346140 DOI: 10.1016/j.hpb.2016.03.609] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 6.0] [Reference Citation Analysis]
4 Renzulli M, Tovoli F, Clemente A, Ierardi AM, Pettinari I, Peta G, Marasco G, Festi D, Piscaglia F, Cappabianca S, Carrafiello G, Golfieri R. Ablation for hepatocellular carcinoma: beyond the standard indications. Med Oncol 2020;37:23. [PMID: 32166482 DOI: 10.1007/s12032-020-01348-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
5 Hijazi H, Campeau MP, Roberge D, Donath D, Lapointe R, Vandenbroucke-Menu F, Taussky D, Boudam K, Chan G, Bujold A, Delouya G. Stereotactic Body Radiotherapy for Inoperable Liver Tumors: Results of a Single Institutional Experience. Cureus 2016;8:e935. [PMID: 28123916 DOI: 10.7759/cureus.935] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
6 Galle PR, Tovoli F, Foerster F, Wörns MA, Cucchetti A, Bolondi L. The treatment of intermediate stage tumours beyond TACE: From surgery to systemic therapy. Journal of Hepatology 2017;67:173-83. [DOI: 10.1016/j.jhep.2017.03.007] [Cited by in Crossref: 69] [Cited by in F6Publishing: 79] [Article Influence: 17.3] [Reference Citation Analysis]
7 Scaggiante B, Farra R, Dapas B, Baj G, Pozzato G, Grassi M, Zanconati F, Grassi G. Aptamer targeting of the elongation factor 1A impairs hepatocarcinoma cells viability and potentiates bortezomib and idarubicin effects. Int J Pharm 2016;506:268-79. [PMID: 27094354 DOI: 10.1016/j.ijpharm.2016.04.031] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
8 Chen RX, Gan YH, Ge NL, Chen Y, Ma M, Zhang BH, Wang YH, Ye SL, Luo JF, Ren ZG. A new prediction model for prognosis of patients with intermediate-stage HCC after conventional transarterial chemoembolization: an internally validated study. J Cancer 2019;10:6535-42. [PMID: 31777583 DOI: 10.7150/jca.34064] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Gao JJ, Shi ZY, Xia JF, Inagaki Y, Tang W. Sorafenib-based combined molecule targeting in treatment of hepatocellular carcinoma. World J Gastroenterol 2015; 21(42): 12059-12070 [PMID: 26576091 DOI: 10.3748/wjg.v21.i42.12059] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 33] [Article Influence: 5.3] [Reference Citation Analysis]
10 Kudo M, Finn RS, Morimoto M, Rau KM, Ikeda M, Yen CJ, Galle PR, Llovet JM, Daniele B, Lim HY, McIlwain DW, Yoshikawa R, Nakamura K, Liang K, Wang C, Abada P, Widau RC, Zhu AX. Ramucirumab for Patients with Intermediate-Stage Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Results from Two Phase 3 Studies (REACH and REACH-2). Liver Cancer 2021;10:451-60. [PMID: 34721507 DOI: 10.1159/000516605] [Reference Citation Analysis]
11 Wang EA, Stein JP, Bellavia RJ, Broadwell SR. Treatment options for unresectable HCC with a focus on SIRT with Yttrium-90 resin microspheres. Int J Clin Pract 2017;71:e12972. [DOI: 10.1111/ijcp.12972] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]